Interstitial iodine 125 and concomitant cisplatin followed by hyperfractionated external beam irradiation for malignant supratentorial glioma : preliminary experience at the University of Tennessee, Memphis

Between November 1989 and October 1992, 28 consecutive patients with glioblastoma multiforme (n=18) or anaplastic astrocytoma (n=10; includes one patient with oligodendroglioma with anaplastic astrocytoma component) were treated with interstitial iodine 125 (60 Gy over 6 days) and with concomitant cisplatin (via infusion on days 2-6 of the implant), then followed by hyperfractionated external beam irradiation (110 cGy delivered twice daily; 66 Gy planned total dose). Of 26 patients (60%) who received both 125 I and HEBI, 15 are alive with no evidence of recurrent disease at a median follow-up of 18 months post- 125 I (range: 11 to 34 months). Four other disease-free patients succumbed to nontumor-related events. Two patients with local control had distant failure outside the HEBI treatment fields